{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
West Pharmaceutical Services, Inc.
West Pharmaceutical Services Forms Death Cross, Signals Bearish Trend Ahead
West Pharmaceutical Services, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. The company's performance has lagged behind the S&P 500, with notable declines over the year and past three years, reflecting ongoing challenges in a turbulent market.
West Pharmaceutical Services Hits Day Low at $228.40 Amid Price Pressure
West Pharmaceutical Services, Inc. faced a significant decline in stock value, with notable decreases over various time frames. Despite these challenges, the company demonstrates strong management efficiency through a high return on equity and maintains a stable financial position with a low debt-to-equity ratio.
West Pharmaceutical Services, Inc. Announces Revision in Stock Evaluation Amid Market Dynamics
West Pharmaceutical Services, Inc. has recently revised its evaluation amid changing market dynamics. The stock is priced at $249.02, showing a 13.33% return over the past year, outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting the company's adaptation to competitive pressures.
Is West Pharmaceutical Services, Inc. overvalued or undervalued?
As of October 17, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a valuation grade of "expensive," reflected in its high P/E ratio of 33 and poor long-term performance, despite recent short-term gains.
West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Metrics
West Pharmaceutical Services, Inc. has adjusted its valuation metrics, with a P/E ratio of 33 and a price-to-book value of 6.12. The company has shown mixed performance, with recent stock returns outperforming the S&P 500, but a year-to-date decline contrasts with broader market gains.
Is West Pharmaceutical Services, Inc. overvalued or undervalued?
As of October 17, 2025, West Pharmaceutical Services, Inc. is considered expensive and overvalued with a P/E ratio of 33, compared to peers, and has underperformed the S&P 500 year-to-date, raising concerns about its valuation outlook.
Is West Pharmaceutical Services, Inc. overvalued or undervalued?
As of October 17, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a valuation grade of "expensive," reflected by a high P/E ratio of 33 and a year-to-date decline of 17.39%, despite a recent positive stock performance.
West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
West Pharmaceutical Services, Inc. has adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology industry. The company exhibits a P/E ratio of 33, a price-to-book value of 6.12, and strong returns on capital and equity, highlighting its competitive position among peers.
Is West Pharmaceutical Services, Inc. overvalued or undervalued?
As of October 10, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a P/E ratio of 33, higher than its peers, and has underperformed the S&P 500 with a return of -9.76% over the past year.
West Pharmaceutical Services, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
West Pharmaceutical Services, Inc. has recently seen a revision in its evaluation, reflecting changes in technical indicators. The stock has shown significant volatility over the past year, with a notable performance disparity compared to the S&P 500, highlighting the challenges the company faces in the competitive Pharmaceuticals & Biotechnology sector.
Is West Pharmaceutical Services, Inc. technically bullish or bearish?
As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, but mixed signals suggest caution due to recent underperformance compared to the S&P 500.
West Pharmaceutical Services Forms Golden Cross, Signaling Bullish Breakout Ahead
West Pharmaceutical Services, Inc. has recently achieved a Golden Cross, indicating a potential shift in investor sentiment. The stock has shown strong short-term performance, outpacing the S&P 500, despite a challenging year-to-date. Bullish indicators suggest possible recovery opportunities in the competitive pharmaceuticals sector.
Is West Pharmaceutical Services, Inc. technically bullish or bearish?
As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, outperforming the S&P 500 recently, but caution is advised due to mixed signals in longer-term performance.
Is West Pharmaceutical Services, Inc. technically bullish or bearish?
As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, although caution is advised due to some bearish signals, while it has outperformed the S&P 500 recently but underperformed over longer periods.
Is West Pharmaceutical Services, Inc. technically bullish or bearish?
As of May 27, 2025, West Pharmaceutical Services, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -22.16% versus the index's 12.22%.
Is West Pharmaceutical Services, Inc. overvalued or undervalued?
As of April 30, 2025, West Pharmaceutical Services, Inc. is fairly valued with a P/E ratio of 33, an EV to EBITDA of 21.43, and an ROE of 18.49%, while its stock has underperformed the S&P 500 with a year-to-date return of -33.84%.
Is West Pharmaceutical Services, Inc. technically bullish or bearish?
As of May 27, 2025, the market trend is mildly bearish, with daily moving averages and weekly Dow Theory indicating bearish sentiment, while mixed signals from the MACD and RSI suggest a cautious outlook with potential for recovery.
Who are in the management team of West Pharmaceutical Services, Inc.?
As of March 2022, the management team of West Pharmaceutical Services, Inc. includes Patrick Zenner (Independent Chairman), Eric Green (CEO), and several Independent Directors: Mark Buthman, William Feehery, Robert Friel, Thomas Hofmann, and Paula Johnson. They are responsible for the company's strategic direction and operations.
What does West Pharmaceutical Services, Inc. do?
West Pharmaceutical Services, Inc. manufactures packaging components and delivery systems for injectable drugs, with net sales of $698 million and a market cap of approximately $15.93 billion as of March 2025. Key financial metrics include a P/E ratio of 33.00 and a dividend yield of 0.38%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
